~12 spots leftby Jul 2025

SABR for Cancer

Recruiting in Palo Alto (17 mi)
Olson, Dr. Robert | UNBC
Overseen byRobert Olson
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: British Columbia Cancer Agency
No Placebo Group

Trial Summary

What is the purpose of this trial?This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).

Eligibility Criteria

This trial is for people with a limited number of cancer spread sites (up to 5), who've had their primary tumor treated, and are not candidates for surgery. They should be in relatively good health otherwise, able to consent, and complete questionnaires in English. Pregnant women or those with certain medical conditions that make radiotherapy unsafe cannot join.

Inclusion Criteria

I can take care of myself and am up and about more than half of the day.
My brain metastases have been approved for treatment by a specialized team.
I only need a PET-CT or PSMA-PET scan for certain conditions.
+26 more

Exclusion Criteria

Pregnant or lactating women
I have signs of pressure on my spinal cord.
My first chemotherapy fully eliminated the cancer that can be measured.
+7 more

Participant Groups

The study tests Stereotactic Ablative Body Radiotherapy (SABR) on patients with few metastatic cancer sites. It aims to assess the side effects and potential survival benefits of this targeted high-dose radiation therapy compared to other treatments.
1Treatment groups
Experimental Treatment
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
BC CancerPrince George, Canada
Loading ...

Who Is Running the Clinical Trial?

British Columbia Cancer AgencyLead Sponsor

References